Overview
Smart money at a glance
Filings to Oct 5, 2026Net selling: insiders sold $1.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$1.7M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $130.11
- 52-wk high
- $140.32
- High
- $132.65
- 52-wk low
- $86.88
- Low
- $128.37
- Prev close
- $129.48
- Mkt cap
- $8.91B
- P/E
- 144.5x
- Volume
- 671.9K
- Beta
- 1.32
- Div yield
- 2.63%
- P/S
- 1.4x
- P/B
- 0.9x
- Profit margin
- +1.6%
- Op margin
- -810.0%
- ROE
- +1.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about JXN filings
Are insiders buying or selling Jackson Financial Inc (JXN) stock?
Net selling: insiders sold $1.7M and bought $0 of JXN stock on the open market in the 90 days to Oct 5, 2026, according to SEC Form 4 filings. The largest was Chelko, Carrie (EVP and General Counsel), who sold $1M. The latest filing was on Aug 13, 2026.
Which members of Congress have traded JXN recently?
None. No member of Congress disclosed a JXN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this JXN smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- BA

Balyasny
$36.0M
added
- CI

Citadel
$24.3M
added
Sells/Trims (1)
- CI

Citadel
$35.6M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in JXN right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 26.7% above what analysts expected.
Last report
Aug 3, 2026
Period ending
Jun 30, 2026
Earnings per share
$5.76 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $7.30 / $5.76Alpha Vantage | +26.74% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $5.15 / $5.96Alpha Vantage | -13.59% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 18, 2026 | $6.61 / $5.70Alpha Vantage | +15.96% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $6.16 / $5.45Alpha Vantage | +13.03% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | $4.87 / $4.64Alpha Vantage | +4.96% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 7, 2025 | -$0.48 / $3.16Alpha Vantage | -115.19% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 19, 2025 | $4.45 / $1.66Alpha Vantage | +$2.79 beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $4.60 / $4.67Alpha Vantage | -1.50% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 3, 2026, in 29 days
Estimates as of Oct 5, 2026
EPS expected
$6.79 to $7.18
Revenue expected
1 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
Is the business strong?
Richly priced and running thin margins.
- Net margin
- 1.6%
- P/E
- 144.54
- Market cap
- $8.9B
Valuation
- P/S1.36
- P/B0.93
- Dividend yield2.6%
Quality
- Operating margin-810.0%
- ROE1.4%
- ROA0.1%
Growth
- Beta1.32
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace